NVAX
2019-01-30WATCHPhase-3 RSV vaccine primary-endpoint miss.
🐜 mostly aggregated. This describes the shape of the order flow — how the accumulation was assembled — not its intent and not its likely outcome. Micro-cap: at $2.18, quotes and EOD data are sparse — treat every reading as low-confidence.
What happened
Watch-level accumulation ahead of the pivotal ResVax readout that failed.
The catalyst: Phase-3 RSV vaccine primary-endpoint miss.
The outcome: 60-day idiosyncratic −88% — a forward idiosyncratic move (beta-stripped vs SPY) over a mature 60-day window. The raw price shown on the chart reached −79%; the two differ because the outcome strips out the market’s beta.
The story behind it
Long before it became a COVID-vaccine name, Novavax was a serial biotech disappointment. In early 2019 it ran into the pivotal Phase-3 readout of ResVax, its RSV vaccine for infants (the 'Prepare' trial). IAS flagged watch-level OTM-put accumulation ahead of the binary.
On January 30, 2019, the trial missed its primary endpoint and the stock lost roughly 70% almost overnight, later doing a reverse split. A clean example of informed positioning into a pass/fail medical event.
Read this honestly
This is a historical, out-of-sample detection shown for illustration. Informed Accumulation is a research and data signal, not investment advice or a recommendation to buy or sell any security, and it does not predict the direction of any single name. AInvest Options Pilot is not a registered investment adviser, broker-dealer, or financial planner. Options involve substantial risk of loss and are not suitable for all investors. Past performance is not indicative of future results.